Surfactant and lung inflammation

Reid, K. B. M.; Clark, H.; Palaniyar, N.
August 2005
Thorax;Aug2005, Vol. 60 Issue 8, p620
Academic Journal
Examines the role of surfactants for the treatment of lung inflammation. Ability of the surfactant system to reduce alveolar surface tension and thereby prevent collapse of the alveoli on expiration; Therapeutic use of exogenous surfactant; Structure of two important human surfactant proteins; Method used for the preparation of functionally active recombinant forms of human surfactant proteins used to treat inflammation.


Related Articles

  • Neonatal chronic lung disease and exogenous surfactant therapy. Greenough, A. // European Journal of Pediatrics. Supplement;1998, Vol. 157, pS16 

    Neonatal chronic lung disease is an important cause of morbidity following premature birth. Surfactant abnormalities, including absence of phosphatidylglycerol and surfactant protein A deficiency, are associated with chronic lung disease. In addition, glycolipids and proteins, inhibitors of...

  • Patients with ARDS show improvement but not normalisation of alveolar surface activity with surfactant treatment: putative role of neutral lipids. Markart, Philipp; Ruppert, Clemens; Wygrecka, Malgorzata; Colaris, Thorsten; Dahal, Bhola; Walmrath, Dieter; Harbach, Heinz; Wilhelm, Jochen; Seeger, Werner; Schmidt, Reinhold; Guenther, Andreas // Thorax;Jul2007, Vol. 62 Issue 7, p588 

    Background: Extensive biochemical and biophysical changes of the pulmonary surfactant system occur in the acute respiratory distress syndrome (ARDS). Methods: The effect of intrabronchial administration of a recombinant surfactant protein C-based surfactant preparation (Venticute) on gas...

  • Budesonide Added to Modified Porcine Surfactant Curosurf May Additionally Improve the Lung Functions in Meconium Aspiration Syndrome. MIKOLKA, P.; MOKRÁ, D.; KOPINCOVÁ, J.; TOMČÍKOVÁ-MIKUŠIAKOVÁ, L.; CALKOVSKÁ, A. // Physiological Research;2013 Supplement, pS191 

    Severe meconium aspiration syndrome (MAS) in newborns is often treated by exogenous surfactant. Because its efficacy is reduced by meconium-induced inflammation, glucocorticoid budesonide was added into surfactant preparation Curosurf to enhance efficacy of the surfactant therapy in experimental...

  • Neonatal Technology, Perinatal Survival, Social Consequences, and the Perinatal Paradox. Kliegman, Robert M. // American Journal of Public Health;Jul1995, Vol. 85 Issue 7, p909 

    Exogenous surfactant therapy for premature infants with respiratory distress syndrome has had a significant impact on infant mortality and on some complications of prematurity. Yet the total number of low-birthweight infants has not declined, resulting in a high-risk population who would require...

  • Surfactant therapy in late preterm infants: respiratory distress syndrome and beyond. Sürmeli.-Onay, Özge; Korkmaz, Ayşe; Yiğit, Şule; Yurdakök, Murat // Turkish Journal of Pediatrics;May/Jun2012, Vol. 54 Issue 3, p239 

    A significant ratio of late preterm infants receives surfactant therapy (ST) for respiratory distress syndrome (RDS) and for other neonatal lung diseases characterized by surfactant inactivation or dysfunction. We aimed to investigate the clinical and therapeutic characteristics and outcomes of...

  • Should critically ill children with acute respiratory failure be treated with surfactant? Ng, Zhi Min; Kavalloor, Nirmal Visrusthan; Lee, Jan Hau // Archives of Disease in Childhood;Jul2013, Vol. 98 Issue 7, p558 

    The article presents an answer to a question should critically ill children with acute respiratory failure be treated with surfactant.

  • Direct and Phagocyte-mediated Lipid Peroxidation of Lung Surfactant by Group B Streptococci. Bouhafs, R. K. L.; Rauprich, P.; Herting, E.; Schr�der, A.; Robertson, B.; Jarstrand, C. // Lung;2000, Vol. 178 Issue 5, p317 

    In newborn infants, group B streptococci (GBS) often cause pneumonia, with polymorphonuclear leukocytes (PMN) migrating into the lungs. Because surfactant therapy may be needed in such patients, we evaluated the interaction between GBS or GBS-stimulated PMN and a surfactant preparation...

  • Lung Surfactants for Neonatal Respiratory Distress Syndrome: Animal-Derived or Synthetic Agents? Suresh, G.K.; Soll, R.F. // Pediatric Drugs;2002, Vol. 4 Issue 8, p485 

    Exogenous surfactant therapy is widely used in the management of neonatal respiratory distress syndrome. Two types of surfactants are available: synthetic surfactants, and those derived from animal sources (‘natural’ surfactants). Both of these surfactants have been shown to be...

  • Outcome study shows benefits of surfactants. Rodgers, Katie // Drug Topics;7/11/94, Vol. 138 Issue 13, p40 

    Reports on the study done by researchers at the National Perinatal Information Center (NPIC) on the efficiency of using surfactant in treating very-low birthweight infants. Decrease of infant mortality nationwide; Availability of surfactant.


Read the Article


Sign out of this library

Other Topics